According to research leader Kenichi Yoshida, this type is a minor variant of T-cell acute lymphoblastic leukemia that develops from immune cells. In the study, which examined over a thousand cases, it was identified in 14 patients aged from 7 to 35 years, with the average age being 17. Yoshida emphasized that the disease falls into a high-risk group and treatment outcomes are often unfavorable.
The main characteristic of this type is that it often goes undetected in standard tests and grows aggressively due to a rare chromosomal change. Modern genetic analysis and hematopoietic stem cell transplantation are of great importance in increasing the possibility of a cure for this disease.
The results obtained by Yoshida are promising for the development of new treatment methods and will help reduce cases of blood cancer among adolescents and adults in the future.
